

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507

 Tel
 :+91 40 4900 2900

 Fax
 :+91 40 4900 2999

 Email
 :mail@drreddys.com

 www.drreddys.com

June 28, 2022

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ) BSE Limited (Scrip Code: 500124)

Dear Sirs,

Sub: Press Release

Please find enclosed a Press Release on "Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F"

This is for your information.


Thanking you.

Yours faithfully, For **Dr. Reddy's Laboratories Limited**

K Randhir Singh Company Secretary & Compliance Officer

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code :RDY) NSE IFSC Ltd.



DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CONTACT

INVESTOR RELATIONS MEDIA RELATIONS

AMIT AGARWAL amita@drreddys.com (PH: +91-40-49002135)

APARNA TEKURI aparnatekuri@drreddys.com (PH: +91-40- 49002446)

Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F

Hyderabad, India, June 28, 2022

For Immediate Release

Hyderabad, India, June 28, 2022: Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended 31 March, 2022 was filed with the United States Securities and Exchange Commission on June 27, 2022.

The Annual Report on Form 20-F is also available on Dr. Reddy's website, www.drreddys.com and can be accessed by selecting 'SEC filings' under 'Reports and Filings' section under 'Investors' tab. American Depositary Receipts (ADRs) holders may also obtain a hard copy of the Annual Report on Form 20-F at no cost, by sending a written request to the Company's registered office or by sending an e-mail to shares@drreddys.com.

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: <u>www.drreddys.com</u>

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."

